Vascular dementia Italian sulodexide study (VA.D.I.S.S.). Clinical and biological results.

In order to evaluate the biological effects on some haemostasis factors of antithrombotic-hemorheological treatments on patients with vascular dementia, a multicenter, randomized, double-blind, double-dummy, study comparing sulodexide (Sdx, 50 mg bid orally for 6 months) and pentoxifylline (Ptx, 400 mg tid orally for six months) was carried out. Eighty-six patients, 46 in Sdx group, 40 in Ptx group, fulfilling the NINDS-AIREN criteria for probable vascular dementia were evaluated. Plasma fibrinogen levels showed a significant reduction in both groups, in patients with high basal levels (> or = 350 mg/dl), the reduction being earlier in Sdx group (2nd month of therapy) than in Ptx group (4th month of therapy).

Posatirelin for the treatment of late-onset Alzheimer's disease: a double-blind multicentre study vs citicoline and ascorbic acid.

Introduction: Posatirelin (L-pyro-2-aminoadipyl-L-leucil-L-prolinamide) a new synthetic tripeptide with cholinergic, catecholaminergic and neurotrophic properties, was investigated in the treatment of Alzheimer's disease.

Material And Methods: A multicentre, double-blind study vs citicoline (reference drug) and ascorbic acid (inactive drug) was carried out in elderly patients suffering from late-onset Alzheimer's disease. The once daily intramuscular treatment lasted for three months followed by one-month oral treatment with a placebo.

RFLPs of the LDL-receptor gene: their use in the diagnosis of FH and in evaluation of different levels of gene expression on normal subjects.

The usefulness of the RFLPs of the LDL-receptor gene in early diagnosis of Familial Hypercholesterolemia (FH) was investigated in 122 FH-families. Four RFLPs, produced by digestion with the enzymes PvuII, ApaLI and AvaII/XbaI were able to detect the affected gene and to follow the inheritance of the disease in 72 out of 97 families (74%). In the remaining 25 families, unambiguous diagnosis was possible in 66% of the cases by use of PvuII, ApaLI and BstEII/EcoRI RFLPs.

Variation in the low density lipoprotein receptor gene is associated with differences in plasma low density lipoprotein cholesterol levels in young and old normal individuals from Italy.

We have used four restriction fragment length polymorphisms (RFLPs) of the human low density lipoprotein receptor (LDL-R) gene, detected by the restriction enzymes Ava II, Pvu II, and ApaLI (5' and 3'), to study the effect of variation at this gene locus in determining plasma cholesterol and LDL cholesterol levels. Two hundred eighty-nine normolipidemic individuals were studied from the Liguria region of Italy. The Pvu II RFLP was significantly associated with differences in plasma total and LDL cholesterol levels, explaining 9.

Use of three DNA polymorphisms of the LDL receptor gene in the diagnosis of familial hypercholesterolemia.

Familial hypercholesterolemia (FH) is an autosomal dominant metabolic disorder caused by several different mutations in the low density lipoprotein (LDL) receptor gene. This large number of different mutations, often undetectable in Southern blotting, makes it impossible directly to diagnose the disease. However, restriction fragment length polymorphisms (RFLPs) can be used to follow the inheritance of the defective gene in FH families.

Effect of a single daily dose treatment of fenofibrate on plasma lipoproteins in hyperlipoproteinaemia IIb.

The safety and efficacy of a single daily dose of fenofibrate (200 mg) have been evaluated in 12 Type IIB hyperlipidaemic patients in a three-month study. At the same time the pharmacokinetics was studied to check whether this new dosage schedule would give a therapeutic plasma levels of fenofibrate. At the single daily dose of 200 mg, fenofibrate was highly effective, very well tolerated, and it reached therapeutic plasma levels without accumulation.

A double-blind placebo controlled evaluation of the safety and efficacy of vinpocetine in the treatment of patients with chronic vascular senile cerebral dysfunction.

In a double-blind clinical trial, vinpocetine, a synthetic ethyl ester of apovincamine, was shown to effect significant improvement in elderly patients with chronic cerebral dysfunction. Forty-two patients received 10 mg vinpocetine three times a day (tid) for 30 days, then 5 mg tid for 60 days. Matching placebo tablets were given to another 42 patients for the 90 day trial period.

Effects of three low-dose oral contraceptive formulations on lipid metabolism.

Three oral contraceptive preparations were studied in 60 healthy women. This randomized, comparative, baseline controlled study was designed to investigate the effects of the preparations on plasma lipids and lipoproteins. The following formulations were studied: a monophasic preparation containing ethinylestradiol and desogestrel (M-DSG) and two triphasic formulations containing ethinylestradiol and gestodene or levonorgestrel respectively (T-GSD and T-LNG).

Lipoprotein changes induced by pantethine in hyperlipoproteinemic patients: adults and children.

Following a brief outline of current knowledge concerning atherosclerosis and its treatment, the authors describe the results obtained by treating with pantethine (900-1200 mg daily for 3 to 6 months) a series of 7 children and 65 adults suffering from hypercholesterolemia alone or associated with hypertriglyceridemia (types IIa and IIb of Fredrickson's classification). Pantethine treatment produced significant reduction of the better known risk factors (total cholesterol, LDL-cholesterol, triglycerides, and apo-B) and a significant increase of HDL-cholesterol (signally HDL2) and apolipoprotein A-I. The authors conclude with a discussion of these results and of the possible role of pantethine in the treatment of hyperlipoproteinemia, in view of its perfect tolerability and demonstrated therapeutic effectiveness.

[Evaluation of the accuracy of precipitation methods for HDL cholesterol determination].

Several methods for HDL-Cholesterol determination have been proposed; the over-floating cholesterol evaluation after non-HDL lipoproteins precipitation by polyanions with bivalent cations or neutral polymers is practical and not expensive, but it's accuracy and precision must be strictly control led. The Authors, after a review and a quality-check of the most used methods, conclude that the best accuracy for HDL-Cholesterol determination is provided by Dextransulphate-Mg-chloride and Phosphotungstate-Mg-chloride at pH 7,5.

[Influence of alcohol intake and smoking on plasma HDL cholesterol in active and sedentary subjects].

The effect of physical activity, of smoking habit and alcohol assumption on plasma HDL-cholesterol has been evaluated in 40 normolipidaemic male active subjects and in 43 non-active ones. The comparison have been performed after covariance adjustment for potentially confounding variables. Physical activity increases and smoking habit decreases HDL-cholesterol plasma levels; no effects depending on alcohol consumption have been found.

[Relationships between programmed physical activity and risk factors in atherosclerosis].

The lipidemic pattern has been evaluated in 40 systematically trained subjects and in 43 subjects of same age and BMI sedentary ones. The mean CT concentration of active subjects was not different from that of the sedentary group, whereas HDL-C was significantly higher and TG significantly lower, CT/HDL-C was significantly lower in active subjects. The obtained results show that systematic physical activity, even if not at agonistic level, can induce antiatherogenic modifications of the lipidemic pattern.

[Altered plasma lipid and protein patterns in schizophrenic patients (author's transl)].

The plasma lipid and lipoprotein pattern (total cholesterol, triglycerides and total lipid concentration; electrophoretic separation of the lipoproteins) and plasma protein profile (total protein concentration; electrophoretic separation of the plasma proteins) have been determined in a group of 60 chronic schizophrenic patients (47 men and 13 women, mean age 30,3 +/- 22 years). When compared to a control group matched for age and sex, the schizophrenic patients exhibited significantly lower cholesterol concentration and altered distribution pattern of the plasma lipid fractions. Similarly, the plasma a1,- a2,- and beta-globulin patterns are also altered in schizophrenic group.